3 Small-Cap Stocks We're Skeptical Of

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here are three small-cap stocks to swipe left on and some alternatives you should look into instead.

CVB Financial (CVBF)

Market Cap: $2.65 billion

With roots dating back to 1974 and a focus on serving small and medium-sized businesses, CVB Financial (NASDAQ:CVBF) operates Citizens Business Bank, providing banking, lending, and trust services to businesses and individuals across California.

Why Do We Steer Clear of CVBF?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 2% annually over the last two years
2. Annual net interest income growth of 2% over the last five years was below our standards for the banking sector
3. Earnings per share have contracted by 2.7% annually over the last two years, a headwind for returns as stock prices often echo long-term EPS performance

CVB Financial is trading at $19.39 per share, or 1.1x forward P/B. Check out our free in-depth research report to learn more about why CVBF doesn’t pass our bar.

Visteon (VC)

Market Cap: $2.48 billion

Originally spun off from Ford Motor Company in 2000, Visteon (NYSE:VC) designs and manufactures cockpit electronics for vehicles, including digital instrument clusters, displays, infotainment systems, and battery management systems.

Why Is VC Not Exciting?

1. Annual sales declines of 2.4% for the past two years show its products and services struggled to connect with the market during this cycle
2. High input costs result in an inferior gross margin of 12% that must be offset through higher volumes
3. Earnings per share have dipped by 25.4% annually over the past two years, which is concerning because stock prices follow EPS over the long term

Visteon’s stock price of $91.96 implies a valuation ratio of 10.6x forward P/E. Dive into our free research report to see why there are better opportunities than VC.

Ocular Therapeutix (OCUL)

Market Cap: $2.40 billion

Pioneering a drug delivery platform that can eliminate the need for monthly eye injections, Ocular Therapeutix (NASDAQ:OCUL) develops sustained-release treatments for eye diseases using its proprietary ELUTYX bioresorbable hydrogel technology that gradually releases medication.

Why Should You Sell OCUL?

1. Sales tumbled by 5.7% annually over the last two years, showing market trends are working against its favor during this cycle
2. Efficiency has decreased over the last five years as its adjusted operating margin fell by 340.5 percentage points
3. Free cash flow margin dropped by 264.1 percentage points over the last five years, implying the company became more capital intensive as competition picked up

At $11.01 per share, Ocular Therapeutix trades at 44.3x forward price-to-sales. If you’re considering OCUL for your portfolio, see our FREE research report to learn more.

Stocks We Like More

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.